Evidence map›Paper›PMID 41783077›Full record

ArticleOphthalmology science2026

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report.

Jan Spindler, Dmitri Artemiev, Isabel B Pfister, Christin Schild, Anne Tillmann, Katharina Heck, Felix Gabathuler, Ludovico Ruscitti, Tahm Spitznagel, Konstantinos Kitsos-Kalyvianakis and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jan SpindlerBerner Augenklinik and Swiss Eye Institute, Bern, Switzerland.
Dmitri ArtemievDepartment of Ophthalmology, Kantonsspital St. Gallen, Switzerland.
Isabel B PfisterBerner Augenklinik and Swiss Eye Institute, Bern, Switzerland.
Christin SchildBerner Augenklinik and Swiss Eye Institute, Bern, Switzerland.
Anne TillmannAugenärzte Praxisgemeinschaft Gutblick AG, Pfaeffikon, Switzerland.
Katharina HeckVista Augenklinik Binningen, Binningen, Switzerland.
Felix GabathulerDepartment of Ophthalmology, University Hospital Zuerich, University of Zuerich, Switzerland.
Ludovico RuscittiEnte Ospedaliero Cantonale (EOC), Ophthalmology Clinic, and Institute of Clinical Neurosciences of Southern Switzerland (INSI) Lugano, Switzerland.
Tahm SpitznagelDepartment of Ophthalmology, Stadtspital Zuerich, Zuerich, Switzerland.
Konstantinos Kitsos-KalyvianakisSwiss Visio Retina Research Center, Swiss Visio Montchoisi, Lausanne, Switzerland.
Marion R MunkAugenärzte Praxisgemeinschaft Gutblick AG, Pfaeffikon, Switzerland.
Katja HatzVista Augenklinik Binningen, Binningen, Switzerland.
Sandrine A ZweifelDepartment of Ophthalmology, University Hospital Zuerich, University of Zuerich, Switzerland.
Gabriela GrimaldiEnte Ospedaliero Cantonale (EOC), Ophthalmology Clinic, and Institute of Clinical Neurosciences of Southern Switzerland (INSI) Lugano, Switzerland.
Gábor Márk SomfaiDepartment of Ophthalmology, Stadtspital Zuerich, Zuerich, Switzerland.
Aude AmbresinSwiss Visio Retina Research Center, Swiss Visio Montchoisi, Lausanne, Switzerland.
Andreas WeinbergerPallas-Klinik Olten, Olten, Switzerland.
Chiara M EandiJules-Gonin Eye Hospital, Fondation Asile des Aveugles, Department of Ophthalmology, University of Lausanne, Switzerland.
Nicolas FeltgenFaculty of Medicine, University of Basel, Basel, Switzerland.
Alice Kitaytazz- Talacker Augen Zentrum Zürich, Zürich, Switzerland.
Andreas EbneterDepartment of Ophthalmology, Kantonsspital St. Gallen, Switzerland.
Justus G GarwegBerner Augenklinik and Swiss Eye Institute, Bern, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate the effectiveness and safety of intravitreal aflibercept 8 mg (Afl 8) for the therapy of treatment-naïve and pretreated diabetic macular edema (DME) in a clinical routine setting. Design: A multicenter, retrospective cohort study of consecutive DME patients treated with Afl 8 over 12 months. Subjects: One hundred fifty-six eyes (124 patients) with DME, including 42 (26.9%) treatment-naïve and 114 (73.1%) pretreated eyes receiving Afl 8 for 1 year. Methods: Data from electronic medical records were collected retrospectively at 5 predefined time points. The primary outcomes were the mean changes in corrected visual acuity (VA), center-point retinal thickness (CRT), central subfield thickness (CST), treatment intervals, and adverse events (AEs). Secondary outcomes included the number of injections, persistent fluid, and treatment adherence. These parameters were recorded from the beginning of anti-VEGF treatment until switching occurred in pretreated eyes. Main Outcome Measures: Mean change in VA, CRT, CST, treatment intervals, and AEs. Results: In treatment-naïve eyes, VA improved from 72.9 ± 10.7 ETDRS letters at baseline to 77.7 ± 9.7 ( Conclusions: Afl 8 offers a promising approach to reducing the treatment burden in DME. It enables extended dosing intervals without compromising efficacy and safety, especially in refractory eyes. However, a possibly increased rate of mild IOI has been observed. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

Aflibercept 8mgAnti-VEGFDiabetic macular edemaSwiss Retina Research NetworkTreatment switch

Identifiers

PMID41783077
PMCPMC12955161

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.